AZ, Daiichi Sankyo sign US Movantik deal
This article was originally published in Scrip
AstraZeneca is teaming up with Daiichi Sankyo, using the Japanese pharma's US-based sales teams and expertise in the primary care setting to commercialize its first-in-class mu-opioid receptor antagonist Movantik (naloxegol) in the US.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.